KLRA
Kailera Therapeutics, Inc.
$18.89
-3.33%
$2.4B
No data for this timeframe.
Vol
Market Cap$2.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (89%)
Insider Activity5B / 0S
Insider Net $$326.8M
Reddit Sentiment67° Warm
SEC Reports20
Press Releases3
Recent Activity
Jun 9, 2026
Insider
Renaud Ronald C JR acquired via exercise 38,094 shares
CEO & President @ $5.25 ($200.0K)
Jun 5, 2026
Press
Kailera Therapeutics and Hengrui Pharma presented positive Phase 2 oral and Phase 1 injection data for ribupatide (GLP-1
Impact 7/10
Jun 5, 2026
fda
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Jun 5, 2026
SEC
Kailera Therapeutics reported Q1 2026 financial results with a net loss of $78.9M, widening from $18.0M in Q1 2025, driv
8-K — Impact 5/10
May 26, 2026
SEC
Kailera Therapeutics reported Q1 2026 net loss of $78.9M vs $18.0M in Q1 2025, with R&D expenses surging to $70.9M from
PRESS-RELEASE — Impact 4/10
May 13, 2026
Press
Kailera Therapeutics and Hengrui Pharma announced two abstracts accepted for poster presentation at the ADA 2026 confere
Impact 4/10
Apr 22, 2026
SEC
Four major insiders at Kailera Therapeutics, including two directors and two 10% owners, collectively purchased $326.75
CLUSTER — Impact 9/10
Apr 20, 2026
Insider
Kaplan Andrew T. acquired 17,857,143 shares
Director
Price Targets
$42.60
+125.5% upside
Strong Buy
Current $18.89
Low $30.00
Median $42.00
High $57.00
5 analysts
$30.00
$57.00
Analyst Ratings
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 12, 2026 | Leerink Partners | INITIATE | Outperform |
| May 12, 2026 | Jefferies | INITIATE | Buy |
| May 12, 2026 | Evercore ISI Group | INITIATE | Outperform |
| May 12, 2026 | JP Morgan | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.72 | $-0.72 — $-0.72 | 1 | |
| Next Q | $-0.89 | $-0.89 — $-0.89 | 1 | |
| Current FY | $-4.29 | $-4.29 — $-4.29 | 1 | |
| Next FY | $-3.73 | $-4.47 — $-2.99 | 13% YoY | 2 |
Latest Reports
BULLISH
Press
7/10
Kailera Therapeutics and Hengrui Pharma presented positive Phase 2 oral and Phase 1 injection data for ribupatide (GLP-1
Jun 5, 2026
NEUTRAL
8-K
5/10
Kailera Therapeutics reported Q1 2026 financial results with a net loss of $78.9M, widening from $18.0M in Q1 2025, driv
Jun 5, 2026
NEUTRAL
PRESS-RELEASE
4/10
Kailera Therapeutics reported Q1 2026 net loss of $78.9M vs $18.0M in Q1 2025, with R&D expenses surging to $70.9M from
May 26, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Renaud Ronald | M | $200.0K |
| Apr 20, 2026 | Kaplan Andrew | C | $0.00 |
| Apr 20, 2026 | Kaplan Andrew | BUY | $134.4M |
| Apr 20, 2026 | Kaplan Andrew | C | $0.00 |
| Apr 20, 2026 | Bain Capital | C | $0.00 |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
17 unique insiders with 35 transactions. Net insider value: $326.8M ($326.8M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Renaud Ronald C JR | CEO & President | EXERCISE | 38,094 | $5.25 | $200.0K |
| Apr 20, 2026 | Kaplan Andrew T. | Director | CONVERT | 17,857,143 | — | — |
| Apr 20, 2026 | Kaplan Andrew T. | Director | BUY | 8,398,438 | $16.00 | $134.4M |
| Apr 20, 2026 | Kaplan Andrew T. | Director | CONVERT | 17,857,143 | — | — |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | CONVERT | 16,875,000 | — | — |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | BUY | 1,562,500 | $16.00 | $25.0M |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | CONVERT | 16,875,000 | — | — |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | CONVERT | 4,145,768 | — | — |
| Apr 20, 2026 | Koppel Adam | Director | CONVERT | 16,875,000 | — | — |
| Apr 20, 2026 | Koppel Adam | Director | BUY | 1,562,500 | $16.00 | $25.0M |
| Apr 20, 2026 | Koppel Adam | Director | CONVERT | 16,875,000 | — | — |
| Apr 20, 2026 | Koppel Adam | Director | CONVERT | 4,145,768 | — | — |
| Apr 20, 2026 | BAIN CAPITAL INVESTORS LLC | 10%+ Owner | CONVERT | 17,857,143 | — | — |
| Apr 20, 2026 | BAIN CAPITAL INVESTORS LLC | 10%+ Owner | BUY | 8,398,438 | $16.00 | $134.4M |
| Apr 20, 2026 | BAIN CAPITAL INVESTORS LLC | 10%+ Owner | CONVERT | 17,857,143 | — | — |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10%+ Owner | CONVERT | 9,477,719 | — | — |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10%+ Owner | CONVERT | 4,968,789 | — | — |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10%+ Owner | CONVERT | 708,814 | — | — |
| Apr 20, 2026 | RTW INVESTMENTS, LP | 10%+ Owner | CONVERT | 10,276,820 | — | — |
| Apr 20, 2026 | RTW INVESTMENTS, LP | 10%+ Owner | BUY | 500,000 | $16.00 | $8.0M |
| Apr 20, 2026 | RTW INVESTMENTS, LP | 10%+ Owner | CONVERT | 8,250,000 | — | — |
| Apr 20, 2026 | RTW INVESTMENTS, LP | 10%+ Owner | CONVERT | 2,026,820 | — | — |
| Apr 16, 2026 | Wasserman Scott M. | Chief Medical Officer | AWARD | 100,000 | — | — |
| Apr 16, 2026 | Pagan Douglas W. | Chief Financial Officer | AWARD | 100,000 | — | — |
| Apr 16, 2026 | Clyburn Frank | Director | AWARD | 38,300 | — | — |
| Apr 16, 2026 | Hite Christopher | Director | AWARD | 38,300 | — | — |
| Apr 16, 2026 | MACKAY MARTIN | Director | AWARD | 38,300 | — | — |
| Apr 16, 2026 | MILLIGAN JOHN F | Director | AWARD | 38,300 | — | — |
| Apr 16, 2026 | Coleman Jamie Beth | Chief Commercial Officer | AWARD | 75,000 | — | — |
| Apr 16, 2026 | Burgess Paul D. | See Remarks | AWARD | 100,000 | — | — |
| Apr 16, 2026 | Renaud Ronald C JR | CEO & President | AWARD | 300,000 | — | — |
| Apr 16, 2026 | Akamine Scott | Chief Legal Officer | AWARD | 60,000 | — | — |
| Apr 16, 2026 | Cloghessy Paula | Chief People Officer | AWARD | 60,000 | — | — |
| Apr 16, 2026 | Kaplan Andrew T. | Director | AWARD | 38,300 | — | — |
| Apr 16, 2026 | Koppel Adam | Director | AWARD | 38,300 | — | — |
20 SEC filing reports analyzed. Sentiment: 5 bullish, 0 bearish, 0 mixed, 15 neutral. Avg impact: 4.5/10.
NEUTRAL
8-K
5/10
Kailera Therapeutics reported Q1 2026 financial results with a net loss of $78.9M, widening from $18
Jun 5, 2026
NEUTRAL
PRESS-RELEASE
4/10
Kailera Therapeutics reported Q1 2026 net loss of $78.9M vs $18.0M in Q1 2025, with R&D expenses sur
May 26, 2026
BULLISH
CLUSTER
9/10
Four major insiders at Kailera Therapeutics, including two directors and two 10% owners, collectivel
Apr 22, 2026
BULLISH
CLUSTER
8/10
Multiple 10% owners and directors of Kailera Therapeutics (KLRA) collectively purchased $318.75 mill
Apr 22, 2026
BULLISH
CLUSTER
8/10
Two insiders, including a director and major shareholder, collectively purchased $159.38 million of
Apr 20, 2026
BULLISH
8-K
8/10
Kailera Therapeutics completed its IPO on April 20, 2026, raising $718.8 million by selling 44,921,8
Apr 20, 2026
BULLISH
424B4
8/10
Kailera Therapeutics has priced its IPO at $16.00 per share, selling 39,062,500 shares to raise $625
Apr 17, 2026
NEUTRAL
EFFECT
5/10
Kailera Therapeutics' IPO has become effective, allowing the company to proceed with its initial pub
Apr 17, 2026
NEUTRAL
3
3/10
Jiangsu Hengrui Pharmaceuticals Co., Ltd. filed a Form 3 disclosing beneficial ownership of Kailera
Apr 17, 2026
NEUTRAL
3
3/10
Adam Koppel, a Partner at Bain Capital Life Sciences Investors, filed a Form 3 disclosing indirect b
Apr 17, 2026
NEUTRAL
3
4/10
Bain Capital Life Sciences has filed an initial Form 3 disclosing beneficial ownership of 21,020,768
Apr 17, 2026
NEUTRAL
3
3/10
Andrew T. Kaplan, a Partner at Bain Capital Investors, LLC, filed a Form 3 disclosing indirect benef
Apr 17, 2026
NEUTRAL
3
3/10
Paul Douglas Burgess, Chief Operating Officer & Chief Business Officer of Kailera Therapeutics, file
Apr 16, 2026
NEUTRAL
3
3/10
Douglas W. Pagán, Chief Financial Officer of Kailera Therapeutics, filed a Form 3 disclosing an opti
Apr 16, 2026
NEUTRAL
3
3/10
RTW Investments, LP and its Managing Partner Roderick Wong filed a Form 3 disclosing beneficial owne
Apr 16, 2026
NEUTRAL
3
3/10
Martin Mackay, Ph.D., a reporting person at Kailera Therapeutics, Inc., filed a Form 3 disclosing an
Apr 16, 2026
NEUTRAL
3
2/10
Christopher Davis Hite, a reporting person at Kailera Therapeutics (KLRA), filed a Form 3 disclosing
Apr 16, 2026
NEUTRAL
3
3/10
Kailera Therapeutics executives Ronald C. Renaud Jr. and Paula Cloghessy filed initial Form 3s discl
Apr 16, 2026
NEUTRAL
3
4/10
Kailera Therapeutics executives Scott Akamine and Frank Clyburn filed initial Form 3 statements disc
Apr 16, 2026
NEUTRAL
3
2/10
John Fairbanks Milligan, a director or officer of Kailera Therapeutics, filed a Form 3 to report ini
Apr 16, 2026
BULLISH
7/10
Kailera Therapeutics and Hengrui Pharma presented positive Phase 2 oral and Phase 1 injection data f
Jun 5, 2026
NEUTRAL
4/10
Kailera Therapeutics and Hengrui Pharma announced two abstracts accepted for poster presentation at
May 13, 2026
NEUTRAL
6/10
Kailera Therapeutics priced its initial public offering of 39,062,500 shares at $16.00 per share, ra
Apr 16, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$42.60 mean target
+125.5% upside
Strong Buy (1.17)
$30.00 Low
$57.00 High
| Metric | Value |
|---|---|
| Current Price | $18.89 |
| Target Low | $30.00 |
| Target Mean | $42.60 |
| Target Median | $42.00 |
| Target High | $57.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.17) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.72 | $-0.72 | $-0.72 | — | — | — | $0.0B | — | 1 |
| Next Q 2026-09-30 |
$-0.89 | $-0.89 | $-0.89 | — | — | — | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-4.29 | $-4.29 | $-4.29 | — | — | — | $0.0B | — | 1 |
| Next FY 2027-12-31 |
$-3.73 | $-4.47 | $-2.99 | 13.0% | — | — | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.720 | |
| 7d ago | $-0.679 | -0.041 |
| 30d ago | $0.000 | -0.720 |
| 60d ago | $0.000 | -0.720 |
| 90d ago | $0.000 | -0.720 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 12, 2026 | Leerink Partners | INITIATE | — | Outperform |
| May 12, 2026 | Jefferies | INITIATE | — | Buy |
| May 12, 2026 | Evercore ISI Group | INITIATE | — | Outperform |
| May 12, 2026 | JP Morgan | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Biggest insider buys this week
▲ 1
💬 0
⚡ 0.5
Jun 5, 2026
fda
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
May 28, 2026
other
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Kailera will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT.
May 26, 2026
earnings
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
May 13, 2026
fda
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
Hengrui Pharma and Kailera Therapeutics announce clinical data presentations at the American Diabetes Association 86th Scientific Sessions
Apr 28, 2026
short_interest
FTD: KLRA — 33,264 shares ($0.8M) failed to deliver
Settlement: 20260428, Price: $23.51, FTD Value: $782,036.64, KAILERA THERAPEUTICS INC COM
Apr 27, 2026
short_volume
Short Volume: KLRA — 76.4% short (0.4M / 0.5M)
Short: 415,936 | Exempt: 11,730 | TRF Vol: 544,176 | Short Ratio: 76.4% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: KLRA — 78.5% short (0.4M / 0.6M)
Short: 432,348 | Exempt: 2,045 | TRF Vol: 550,461 | Short Ratio: 78.5% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
offering
Kailera Therapeutics Announces Pricing of Initial Public Offering
Kailera Therapeutics, Inc. (Nasdaq: KLRA) today announced the pricing of its initial public offering.